HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Supplemental Data All Versions of this Article: jnumed.108.060418v1 50/6/991    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by McBride, W. J. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by McBride, W. J. Articles by Goldenberg, D. M.

A Novel Method of ¹⁸F Radiolabeling for PET

¹ Immunomedics, Inc., Morris Plains, New Jersey; ² Center for Molecular Medicine and Immunology, Garden State Cancer Center, Belleville, New Jersey; ³ IBC Pharmaceuticals, Inc., Morris Plains, New Jersey; and ⁴ Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Correspondence: For correspondence or reprints contact: William J. McBride, Immunomedics, Inc., 300 American Way, Morris Plains, NJ 07950. E-mail: bmcbride{at}immunomedics.com

Small biomolecules are typically radiolabeled with ¹⁸F by binding it to a carbon atom, a process that usually is designed uniquely for each new molecule and requires several steps and hours to produce. We report a facile method wherein ¹⁸F is first attached to aluminum as Al¹⁸F, which is then bound to a chelate attached to a peptide, forming a stable Al¹⁸F-chelate-peptide complex in an efficient 1-pot process. Methods: For proof of principle, this method was applied to a peptide suitable for use in a bispecific antibody pretargeting method. A solution of AlCl₃·6H₂O in a pH 4.0 sodium-acetate buffer was mixed with an aqueous solution of ¹⁸F to form the Al¹⁸F complex. This was added to a solution of IMP 449 (NOTA-p-Bn-CS-D-Ala-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-NH₂) (NOTA-p-Bn-CS is made from S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid; HSG is histamine-succinyl-glycine) and heated to 100°C for 15 min. In vitro and in vivo stability and targeting ability of the Al¹⁸F-IMP 449 were examined in nude mice bearing LS174T human colonic tumors pretargeted with an anti-CEACAM5 bispecific antibody (TF2). Results: The radiolabeled peptide was produced in 5%–20% yield with an estimated specific activity of 18,500–48,100 GBq (500–1,300 Ci)/mmol. The Al¹⁸F-IMP 449 was stable for 4 h in serum in vitro, and in animals, activity isolated in the urine 30 min after injection was bound to the peptide. Nonchelated Al¹⁸F had higher tissue uptake, particularly in the bones, than the chelated Al¹⁸F-IMP 449, which cleared rapidly from the body by urinary excretion. Tumor uptake was 30-fold higher with TF2-pretargeted Al¹⁸F-IMP 449 than with the peptide alone. Dynamic PET showed tumor localization within 30 min and rapid and thorough clearance from the body. Conclusion: The ability to bind highly stable Al¹⁸F to metal-binding ligands is a promising new labeling method that should be applicable to a diverse array of molecules for PET.

Key Words: bispecific antibody • cancer • CEACAM5 • ¹⁸F • pretargeting • molecular imaging • PET

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]